CD19 and B-cell chronic lymphocytic leukemia: Therefore, CD19 targeted CAR T cells have been extensively evaluated for treatment of hematological cancers such as acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma, chronic lymphocytic leukemia, and B cell non-Hodgkin lymphomas [99,148].